Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.

Authors:
  • CSC A Stringer
    C A Stringer
  • CMC M Matthews
    C M Matthews
  • DWD L Willis
    D L Willis
  • JNJ Nemunaitis
    J Nemunaitis

Abstract
PURPOSETo determine the maximum-tolerable dose (MTD) of paclitaxel in a phase I dose-escalation study when combined with cisplatin in patients with advanced ovarian cancer receiving filgrastim for ...